Skip to main content
Premium Trial:

Request an Annual Quote

Merck Taps Dana-Farber for Genomic Analysis of Cancer Therapeutics

NEW YORK (GenomeWeb News) – The Dana-Farber Cancer Institute will use cross-species genomic analysis and validation testing in a cancer drug collaboration with Merck, the Institute said today.
 
Under the agreement, Merck will provide the Center for Applied Cancer Science at Dana-Farber with up-front and research support funding and with milestone and royalty payments if a drug is approved for marketing. CACS will retain the right to develop its antibodies independently from the collaboration with Merck.
 
The CACS will work with Merck to develop assays for lead compound discovery, and then test the drugs in its model systems that “closely replicate human disease,” CACS said.
 
CACS faculty will work with Merck to further evaluate tumor pathobiology and clinical outcomes to better pinpoint the tumor types that are most susceptible to drug candidates.
 
Further terms of the alliance were not disclosed.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.